NIABY vs MDGL
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NIABY · NIBE INDUSTRIER AB UNSPN ADS EACH REP 1 ORD SHS$4.57 ▼ 0.31%
MDGL · Madrigal Pharmaceuticals$399.63 ▼ 0.12%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NIABY +16.4%
- MDGL -19.4%
Head to head
| Metric | NIABY | MDGL |
|---|---|---|
| Price | $4.57 | $399.63 |
| Change today | ▼ 0.31% | ▼ 0.12% |
| Market cap | $9.27B | $9.28B |
| Return, 3 months | +8.7% | -22.5% |
| Return, year to date | +26.7% | -31.4% |
| Return, 1 year | +22.3% | -18.3% |
| P/E (TTM) | 32.6 | – |
| P/B | 0.3 | 14.8 |
| P/E percentile vs own 5y | – | 24th |
| Dividend yield | 0.82% | – |
| Revenue growth (YoY, latest qtr) | – | +71.2% |
| Net profit growth (YoY) | – | -37.0% |
| Gross margin | – | 91.5% |
| Operating margin | – | -25.1% |
| Net margin | – | -25.3% |
| Return on equity | – | -53.3% |
| Analyst target vs. price | – | +71.9% |
| Analyst buy share | – | 89% |
| RSI (14) | 50 | 24 |
| 30-day volatility | 36.4% | 34.2% |
| Max drawdown, 1 year | -31.4% | -34.3% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MDGL is the largest of the group by market value.
- NIABY has returned the most over the past year.
- MDGL has been the calmest stock over the last 30 days.